



**Fuji Pharma Co., Ltd.**

## **Announcement on transfer of marketing authorization for antiepileptic agent “GABAPEN<sup>®</sup> Tablets/Syrup” from Pfizer to Fuji Pharma**

TOKYO, December 6, 2018 -- Pfizer Japan Inc. (Head office: Shibuya-ku, Tokyo / President&CEO: Akihisa Harada; hereinafter “Pfizer”) and Fuji Pharma Co., Ltd. (Head office: Chiyoda-ku, Tokyo / President&CEO: Eiji Takemasa; hereinafter “Fuji Pharma”) announce that both companies agreed to transfer the marketing authorization in Japan for an antiepileptic agent marketed by Pfizer, “GABAPEN<sup>®</sup> Tablets 200 mg, 300 mg, and 400 mg and Syrup 5%” (generic name: gabapentin), from Pfizer to Fuji Pharma. The distribution, in addition to the marketing authorization, of this product will also be transferred from Pfizer to Fuji Pharma after a certain preparatory period.

GABAPEN is an antiepileptic agent synthesized in Germany in 1973. In Japan, the drug was approved in July and launched in September 2006 for the indication of “Combination therapy with antiepileptic drugs for partial seizures (including secondary generalized seizure) in patients with epilepsy for whom other antiepileptic drugs are not sufficiently effective.” Thereafter, the dosage and administration for children aged 3 years or older was approved for the same indication in July 2011, and at the same time the syrup preparation as a dosage form easy to take and appropriate to adjust the dose was developed to be approved and launched in October 2011.

Fuji Pharma announced the expansion of its business into rare diseases mainly in children in the long-term vision “FujiPharma2030” established in this year and will develop the business based on the transfer of the marketing authorization of this time. Pfizer continues the marketing of the product and activities to provide and collect information to and from medical institutions, etc. for some time to come. Fuji Pharma will take over the marketing authorization and distribution of the product when the preparations are completed. At the current moment, the marketing authorization and distribution are planned to be transferred by the end of 2019, and details will be announced as soon as the decision is made.

Pfizer and Fuji Pharma will cooperate for a smooth transfer of the marketing authorization for GABAPEN to continue the efforts to stably supply products, provide the product information, and promote the appropriate use of them.

### **About Pfizer: Working together for a healthier world®**

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at [www.pfizer.com](http://www.pfizer.com). In addition, to learn more, please visit us on [www.pfizer.com](http://www.pfizer.com) and follow us on Twitter at @Pfizer and @Pfizer\_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

### **About Fuji Pharma**

Fuji Pharma is a pharmaceutical company focused on the development, manufacturing, and marketing of new drugs, generic drugs and biosimilars. Besides the company is also active in the fields of medical care for women and acute medical care. In the women's healthcare area, Fuji Pharma distributes a variety of new and generic drugs for gynopathy, aiming to become the leading company of the women medical care in the Japanese market, by supporting the health of women at a wide age range. In the acute medical care area, Fuji Pharma expands their brand mainly in the diagnosis and oncology field.

Fuji Pharma acquired OLIC (Thailand) Limited, the largest Thai Contract Manufacturing Organization in October 2012, which manufactures pharmaceutical products both in Toyama Plant in Japan and OLIC in Thailand. Especially having the strengths on manufacturing injection and hormonal products. Fuji Pharma is listed on the First Section of the Tokyo Stock Exchange. The annual consolidated revenues in 2018 is 37.9 billion Yen and the operating profit is 4.3 billion Yen. For more information please visit the site <https://www.fujipharma.jp/english/ir/>.

**Contact:**

Pfizer Japan Inc.

Communications & Country Manager Office

Yuko Yoneyama

Tel: +81-90-9146-2473

E-mail: [yuko.yoneyama@pfizer.com](mailto:yuko.yoneyama@pfizer.com)

Minoru Suzuki

Tel: +81-80-5538-6513

E-mail: [minoru.suzuki@pfizer.com](mailto:minoru.suzuki@pfizer.com)

Fuji Pharma Co., Ltd.

Corporate Planning Dept.

Tel: +81-3-3556-3344

E-mail: [fsk\\_ir@fujipharma.jp](mailto:fsk_ir@fujipharma.jp)